Back to top
more

Entasis Therapeutics Holdings Inc. (ETTX)

(Delayed Data from NSDQ)

$6.74 USD

6.74
19,212

-0.14 (-2.02%)

Updated May 3, 2019 04:13 PM ET

After-Market: $6.93 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[ETTX]

Reports for Purchase

Showing records 1 - 20 ( 70 total )

Industry: Medical - Drugs

Record: 1

07/12/2022

Company Report

Pages: 4

Acquisition by Innoviva Closes; Terminating Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

04/28/2022

Daily Note

Pages: 16

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

04/28/2022

Company Report

Pages: 5

Q1 Financials; ATTACK Updates at ECCMID

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

04/28/2022

Company Report

Pages: 7

1Q Recap; SUL-DUR''s NDA Filing On Target in Mid-2022; Maintain Neutral, Adjusting PT to $2 Based on Innoviva''s New Offer

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

04/27/2022

Daily Note

Pages: 4

ECCMID Presentations Highlight SUL-DUR''s Safety and Efficacy; NDA Filing Expected in Mid-2022; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

03/08/2022

Company Report

Pages: 6

Q4 Financials; Downgrading to NEUTRAL on Acquisition Proposal

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

03/08/2022

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

03/04/2022

Company Report

Pages: 7

4Q Recap: We Expect Innoviva''s Acquisition to Close, As Proposed; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

11/05/2021

Company Report

Pages: 8

3Q21 Recap; U.S. Commercial Preparations Now Underway For SUL-DUR; NDA Filing Expected Mid-2022; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

11/04/2021

Company Report

Pages: 6

Q3 Financials; ATTACK on Acinetobacter in 2022

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

10/19/2021

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

10/19/2021

Company Report

Pages: 6

No Surprise ATTACK! Ph 3 Positive on all Fronts

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

10/19/2021

Company Report

Pages: 6

ATTACK for the Win: Positive Pivotal Results Tees up a mid-2022 NDA Submission

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

10/19/2021

Company Report

Pages: 6

ATTACK Results Support Clear Commercial Opportunity

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ETTX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

09/16/2021

Daily Note

Pages: 4

Nature Publication Highlights ETX0462 and Entasis''Innovative Drug Design Process; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

08/25/2021

Company Report

Pages: 9

KOL Event Highlights Urgent Need For Safe And Effective Treatment Against CRAB

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

08/16/2021

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

08/16/2021

Company Report

Pages: 5

Q2 Financials; Topline ATTACK Data Early Q4:21

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

08/13/2021

Company Report

Pages: 8

2Q21 Recap: SUL-DUR U.S. Launch Preparation Begins As ATTACK Top-line Data on Target for Early 4Q21; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party
// eof